Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens.

Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens. Reumatismo. 2019 Jul 09;71(2):62-67 Authors: Schioppo T, Scalone L, Cozzolino P, Mantovani L, Cesana G, De Lucia O, Murgo A, Ingegnoli F Abstract Systemic sclerosis (SSc)-related Raynaud's phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months' follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months)...
Source: Reumatismo - Category: Rheumatology Authors: Tags: Reumatismo Source Type: research